A Phase 2 study evaluating ME-344 plus Avastin in patients with relapsed colorectal cancer
Latest Information Update: 19 Jun 2023
At a glance
- Drugs Bevacizumab (Primary) ; ME 344 (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
Most Recent Events
- 15 Jun 2023 According to a MEI Pharma media release, Mr. David Urso will provide an update on the pending merger and an overview of the combined company, which joins the expertise and resources of MEI and Infinity to advance a robust pipeline of three clinical-stage oncology drug candidates.
- 08 Sep 2022 According to a MEI Pharma media release, the company expect to initiate this trial in the first half of calendar year 2023.
- 13 Apr 2022 New trial record